3 enrolling by invitation. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Enrolling by invitation 3 |
Follow Glucose Metabolism Disorders: new trials by email Literature Review of Glucose Metabolism Disorders trials Research Report on Glucose Metabolism Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension SPC1001 Low, SPC5002, SPC5003 - Hypertension (HTN), NYHA Class III Heart Failure | Phase 2 | Enrolling by invitation | Shin Poong Pharmaceutical Co. Ltd. | 252 | 2024-12-05 | 2025-07-14 |
| Dapagliflozin Effect on Glucose Variability in Patients Post Bariatric Surgery Dapagliflozin 10 MG - Bariatric Surgery Candidate, Type2 Diabetes | Phase 2 | Enrolling by invitation | Dasman Diabetes Institute | 30 | 2019-10-22 | 2026-04-07 |
| Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind. 18F-MK6240 injection - Diabetes Mellitus, Type 2, Pre-diabetes | Phase 2 | Enrolling by invitation | Columbia University | 600 | 2018-07-24 | 2025-05-06 |
Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Glucose Intolerance (1) · Hyperglycemia (1) · Hypertension (1) · Pick Disease of the Brain (1)
Endocrine System Diseases (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Diabetes Mellitus (1) · Frontotemporal Dementia (1) · Frontotemporal Lobar Degeneration (1) · Mental Disorders (1) · Nervous System Diseases (1) · Neurocognitive Disorders (1) · Vascular Diseases (1)
MK-6240 (1) · SPC 5002 (1) · dapagliflozin (1)
Columbia University (1) · Dasman Diabetes Institute (1) · Shin Poong Pharmaceutical Co. Ltd. (1)
Kuwait (1) · South Korea (1) · United States (1)
R01AG050440 (1), R01AG055299 (1), RF1AG051556 (1)